PBE: AI 评分 47/100 — AI 分析 (4月 2026)

The Invesco Biotechnology & Genome ETF (PBE) aims to provide capital appreciation by investing in US biotechnology and genome companies. The fund tracks the Dynamic Biotech & Genome Intellidex Index, rebalanced quarterly.

Key Facts: AI Score: 47/100 Sector: Financial Services

公司概况

概要：

Invesco Biotechnology & Genome ETF (PBE) seeks capital appreciation by investing in a portfolio of approximately 30 U.S. biotechnology and genome companies, tracking the Dynamic Biotech & Genome Intellidex Index, which uses investment merit criteria like price and earnings momentum, quality, management action, and value.

PBE是做什么的？

The Invesco Biotechnology & Genome ETF (PBE) is designed to provide investors with exposure to the biotechnology and genome sectors. Launched by Invesco, a well-established asset management firm, the fund operates by tracking the Dynamic Biotech & Genome Intellidex Index. This index focuses on U.S.-based companies that are principally engaged in the research, development, manufacture, and marketing of biotechnological products, services, and processes, as well as companies that benefit significantly from advances in biotechnology and genetic engineering. The ETF invests at least 90% of its total assets in the securities that comprise the Index. The Index employs a quantitative methodology, evaluating companies based on factors such as price momentum, earnings momentum, quality, management action, and value to identify those with the greatest potential for capital appreciation. The fund is rebalanced and reconstituted quarterly in February, May, August, and November, ensuring that the portfolio remains aligned with the index's criteria and reflects the latest market dynamics. PBE offers investors a way to gain diversified exposure to the biotechnology and genome sectors without having to individually select stocks, making it a convenient option for those seeking to participate in the growth of these industries.

PBE的投资论点是什么？

The Invesco Biotechnology & Genome ETF (PBE), with a market capitalization of $0.26 billion and a beta of 1.07, presents a targeted investment vehicle for exposure to the biotechnology and genome sectors. The fund's strategy of tracking the Dynamic Biotech & Genome Intellidex Index, which selects companies based on factors like price and earnings momentum, aims to capture capital appreciation. The quarterly rebalancing schedule ensures the portfolio remains aligned with current market conditions. A key consideration is the absence of dividend yield, making it less attractive for income-focused investors. Growth is tied to the performance of the underlying biotechnology and genome companies, influenced by factors such as regulatory approvals, clinical trial outcomes, and technological advancements. Investors should monitor the performance of the index and the overall health of the biotechnology and genome industries.

PBE在哪个行业运营？

The Invesco Biotechnology & Genome ETF (PBE) operates within the asset management industry, specifically focusing on the biotechnology and genome sectors. These sectors are characterized by high growth potential driven by advancements in genetic engineering, personalized medicine, and biopharmaceuticals. The competitive landscape includes other specialized ETFs and mutual funds that target similar segments of the market. The biotechnology industry is subject to regulatory scrutiny, clinical trial risks, and patent expirations, all of which can impact the performance of companies within the sector. PBE offers a diversified approach to investing in this dynamic and rapidly evolving industry.

Asset Management

Financial Services

PBE有哪些增长机遇？

Increased Investment in Biotechnology Research and Development: Global investment in biotechnology R&D is projected to continue its upward trajectory, fueled by the demand for innovative therapies and diagnostics. This trend presents a significant growth opportunity for companies within the PBE portfolio. As these companies secure funding and advance their pipelines, their stock prices could appreciate, driving up the ETF's overall value. The timeline for realizing this growth is ongoing, with continuous advancements and breakthroughs expected in the coming years. The ETF benefits from diversification across multiple companies, mitigating the risk associated with individual company performance.
Advancements in Gene Editing Technologies: The rapid development and application of gene editing technologies, such as CRISPR-Cas9, are revolutionizing the treatment of genetic diseases. Companies at the forefront of this field have the potential to generate substantial revenue through licensing agreements, partnerships, and the development of novel therapies. This growth opportunity is expected to unfold over the next 5-10 years as gene editing technologies mature and gain wider acceptance. PBE's exposure to companies involved in gene editing positions it to benefit from this transformative trend.
Growing Demand for Personalized Medicine: The shift towards personalized medicine, where treatments are tailored to an individual's genetic makeup, is creating new opportunities for biotechnology companies. Diagnostic tests and targeted therapies are becoming increasingly important in healthcare, driving demand for companies specializing in these areas. This trend is expected to accelerate over the next decade as personalized medicine becomes more integrated into clinical practice. PBE's focus on biotechnology and genome companies aligns it with this growing demand, potentially leading to increased returns for investors.
Aging Population and Increased Healthcare Spending: The global population is aging, leading to a greater prevalence of age-related diseases and increased healthcare spending. This demographic shift is creating a favorable environment for biotechnology companies that develop treatments for conditions such as cancer, Alzheimer's disease, and cardiovascular disease. The demand for these therapies is expected to rise steadily in the coming years, providing a long-term growth opportunity for PBE. The ETF's diversified portfolio helps to capture the potential upside from multiple companies addressing these healthcare needs.
Expansion into Emerging Markets: Emerging markets are experiencing rapid economic growth and increasing access to healthcare, creating new opportunities for biotechnology companies. As these markets adopt advanced medical technologies and treatments, the demand for biotechnology products and services is expected to rise. Companies within the PBE portfolio that successfully expand into emerging markets could experience significant revenue growth. This growth opportunity is expected to unfold over the next 5-10 years as emerging markets continue to develop their healthcare infrastructure.

Market Cap of $0.26B indicates a mid-sized ETF within the biotechnology and genome sector.
Beta of 1.07 suggests the ETF's price is slightly more volatile than the overall market.
The ETF invests at least 90% of its assets in securities comprising the Dynamic Biotech & Genome Intellidex Index.
Quarterly rebalancing in February, May, August, and November ensures the portfolio remains aligned with the index's criteria.
Absence of dividend yield may make it less attractive for income-focused investors.

PBE提供哪些产品和服务？

Invests in U.S. biotechnology and genome companies.
Tracks the Dynamic Biotech & Genome Intellidex Index.
Provides capital appreciation through investments.
Rebalances and reconstitutes its portfolio quarterly.
Focuses on companies engaged in biotechnology research, development, and manufacturing.
Targets companies benefiting from advances in genetic engineering.

PBE如何赚钱？

Generates revenue through management fees charged to investors.
Aims to outperform its benchmark index, the Dynamic Biotech & Genome Intellidex Index.
Attracts investors seeking exposure to the biotechnology and genome sectors.
Rebalances portfolio quarterly to maintain alignment with the index.

Individual investors seeking exposure to the biotechnology and genome sectors.
Institutional investors looking for diversified investment options.
Financial advisors seeking to build portfolios for their clients.
Retirement funds and pension plans.

Index-tracking strategy provides a defined and transparent investment approach.
Diversification across multiple biotechnology and genome companies reduces risk.
Established brand and reputation of Invesco as an asset manager.
Quarterly rebalancing ensures the portfolio remains aligned with the index's criteria.

什么因素可能推动PBE股价上涨？

Ongoing: Continuous advancements in biotechnology and genetic engineering driving innovation.
Upcoming: Quarterly rebalancing in May 2026 to adjust portfolio based on index criteria.
Ongoing: Growing demand for personalized medicine and targeted therapies.

PBE的主要风险是什么？

Potential: Regulatory setbacks and clinical trial failures impacting portfolio companies.
Potential: Market volatility and economic downturns affecting investor sentiment.
Potential: Patent expirations and competition from generic drugs.
Ongoing: Dependence on the performance of underlying biotechnology and genome companies.

PBE的核心优势是什么？

Exposure to high-growth biotechnology and genome sectors.
Diversification across multiple companies reduces risk.
Transparent index-tracking strategy.
Quarterly rebalancing ensures portfolio alignment.

PBE的劣势是什么？

Subject to volatility in the biotechnology and genome sectors.
Absence of dividend yield may deter income-focused investors.
Performance is dependent on the success of the underlying companies.
Expense ratio reduces overall returns.

PBE有哪些机遇？

Increased investment in biotechnology R&D.
Advancements in gene editing technologies.
Growing demand for personalized medicine.
Expansion into emerging markets.

PBE面临哪些威胁？

Regulatory hurdles and clinical trial risks.
Patent expirations and competition from generic drugs.
Economic downturns and market volatility.
Changes in healthcare policy and reimbursement rates.

PBE的竞争对手是谁？

American Century STOXX U.S. Security Income ETF — Focuses on security income rather than biotechnology. — (AVSD)
Calamos Antetokounmpo Global Sustainable Equities ETF — Employs a global sustainable equities strategy. — (CLSE)
Direxion Daily Energy Bull 2X Shares — Provides leveraged exposure to the energy sector. — (DEXC)
AdvisorShares Dorsey Wright FSM US Core ETF — Utilizes a core U.S. equity strategy. — (EDOW)
IQ Candriam ESG US Equity ETF — Focuses on ESG (Environmental, Social, and Governance) factors. — (IQSI)

Key Metrics

MoonshotScore: 47/100

Company Profile

Headquarters: Wheaton, US
Founded: 2005

AI Insight

AI analysis pending for PBE

常见问题

What does Invesco Biotechnology & Genome ETF do?

The Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund that seeks to provide capital appreciation by investing in a portfolio of U.S. biotechnology and genome companies. The fund tracks the Dynamic Biotech & Genome Intellidex Index, which uses a quantitative methodology to select companies based on factors such as price momentum, earnings momentum, quality, management action, and value. PBE offers investors a way to gain diversified exposure to the biotechnology and genome sectors without having to individually select stocks. The fund is rebalanced quarterly to maintain alignment with the index.

What do analysts say about PBE stock?

AI analysis is pending for PBE. Generally, ETFs are evaluated based on the performance of their underlying assets and the overall health of the sectors they track. Investors should monitor the performance of the Dynamic Biotech & Genome Intellidex Index, as well as the financial health and growth prospects of the biotechnology and genome companies within the portfolio. Key valuation metrics to consider include the ETF's price-to-earnings ratio and price-to-book ratio, relative to its peers and the broader market. Analyst ratings and price targets for the individual companies within the portfolio can also provide valuable insights.

What are the main risks for PBE?

The Invesco Biotechnology & Genome ETF (PBE) is subject to several risks inherent in the biotechnology and genome sectors. These include regulatory hurdles, clinical trial failures, patent expirations, and competition from generic drugs. Market volatility and economic downturns can also impact investor sentiment and the ETF's performance. Additionally, the fund's performance is dependent on the success of the underlying companies within the portfolio. Investors should be aware of these risks and carefully consider their investment objectives and risk tolerance before investing in PBE.